Ben Gold

Ben Gold

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2017 in Microbiology Spectrum
Verified
Journal Article
Closed access
BGBen Gold
Ben Gold
CNCarl Nathan
Carl Nathan
While the immune system is credited with averting tuberculosis in billions of individuals exposed toMycobacterium tuberculosis, the immune system is also culpable for tempering the ability of antibiotics to deliver swift and durable cure of disease. In individuals afflicted with tuberculosis, host immunity produces diverse microenvironmental niches that support suboptimal growth, or complete growth arrest, ofM. tuberculosis. The physiological state of nonreplication in bacteria is associated with phenotypic drug tolerance. Many of these host microenvironments, when modeled in vitro by carbon starvation, complete nutrient starvation, stationary phase, acidic pH, reactive nitrogen intermediates, hypoxia, biofilms, and withholding streptomycin from the streptomycin-addicted strain SS18b, renderM. tuberculosisprofoundly tolerant to many of the antibiotics that are given to tuberculosis patients in clinical settings. Targeting nonreplicating persisters is anticipated to reduce the duration of antibiotic treatment and rate of posttreatment relapse. Some promising drugs to treat tuberculosis, such as rifampin and bedaquiline, only kill nonreplicatingM. tuberculosisin vitroat concentrations far greater than their minimal inhibitory concentrations against replicating bacilli. There is an urgent demand to identify which of the currently used antibiotics, and which of the molecules in academic and corporate screening collections, have potent bactericidal action on nonreplicatingM. tuberculosis. With this goal, we review methods of high-throughput screening to target nonreplicatingM. tuberculosisand methods to progress candidate molecules. A classification based on structures and putative targets of molecules that have been reported to kill nonreplicatingM. tuberculosisrevealed a rich diversity in pharmacophores.

21 February 2018 in ACS Infectious Diseases
Verified
Journal Article
Open access
TLTania J. Lupoli
Tania J. Lupoli
JVJulien Vaubourgeix
Julien Vaubourgeix
KBKristin Burns-Huang
Kristin Burns-Huang
BGBen Gold
Ben Gold
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the world’s deadliest infectious diseases and urgently requires new antibiotics to treat drug-resistant strains and to decrease the duration of therapy. During infection, Mtb encounters numerous stresses associated with host immunity, including hypoxia, reactive oxygen and nitrogen species, mild acidity, nutrient starvation, and metal sequestration and intoxication. The Mtb proteostasis network, composed of chaperones, proteases, and a eukaryotic-like proteasome, provides protection from stresses and chemistries of host immunity by maintaining the integrity of the mycobacterial proteome. In this review, we explore the proteostasis network as a noncanonical target for antibacterial drug discovery.

1 February 2019 in Science
Verified
Journal Article
Open access
PDF file
EBElaine Ballinger
Elaine Ballinger
JMJohn Mosior
John Mosior
THTravis Hartman
Travis Hartman
KBKristin Burns-Huang
Kristin Burns-Huang
BGBen Gold
Ben Gold
CNCarl Nathan
Carl Nathan
A wrench in the gears of life: Tuberculosis is a global health crisis that threatens to become worse as resistance to existing drugs emerges. Identifying ideal targets for drug development requires knowledge of weak points in biochemical pathways that are specific for the pathogen but are absent in hosts. Ballinger et al. identified a small molecule that inhibits the enzyme phosphopantetheinyl transferase (PptT), which is crucial for biosynthesis of mycobacterial structural and virulence lipids (see the Perspective by Mizrahi and Warner). Treatment resulted in selective killing of the bacteria in vitro and in a mouse model. The target pathways were made sensitive to PptT inhibition by a second enzyme, phosphopantetheine hydrolase, whose activity opposes that of the transferase. Science , this issue p. eaau8959 ; see also p. 457

14 February 2015
Verified
Book Chapter
Closed access
PDF file
BGBen Gold
Ben Gold
TWThulasi Warrier
Thulasi Warrier
CNCarl Nathan
Carl Nathan

24 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
KSKohta Saito
Kohta Saito
SMSaurabh Mishra
Saurabh Mishra
TWThulasi Warrier
Thulasi Warrier
NCNico Cicchetti
Nico Cicchetti
JMJianjie Mi
Jianjie Mi
CNCarl Nathan
Carl Nathan
Mycobacterium tuberculosis that sustains moderate oxidative damage survives undetected on solid media, but growth delay restores replicative ability.

1 October 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
BGBen Gold
Ben Gold
JRJulia Roberts
Julia Roberts
YLYan Ling
Yan Ling
LQLandys Lopez Quezada
Landys Lopez Quezada
JGJou Glasheen
Jou Glasheen
CNCarl Nathan
Carl Nathan
The search for drugs that can kill replicating and nonreplicating Mycobacterium tuberculosis faces practical bottlenecks. Measurement of CFU and discrimination of bacteriostatic from bactericidal activity are costly in compounds, supplies, labor, and time. Testing compounds against M. tuberculosis under conditions that prevent the replication of M. tuberculosis often involves a second phase of the test in which conditions are altered to permit the replication of bacteria that survived the first phase. False-positive determinations of activity against nonreplicating M. tuberculosis may arise from carryover of compounds from the nonreplicating stage of the assay that act in the replicating stage. We mitigate these problems by carrying out a 96-well microplate liquid MIC assay and then transferring an aliquot of each well to a second set of plates in which each well contains agar supplemented with activated charcoal. After 7 to 10 days—about 2 weeks sooner than required to count CFU—fluorometry reveals whether M. tuberculosis bacilli in each well have replicated extensively enough to reduce a resazurin dye added for the final hour. This charcoal agar resazurin assay (CARA) distinguishes between bacterial biomasses in any two wells that differ by 2 to 3 log 10 CFU. The CARA thus serves as a pretest and semiquantitative surrogate for longer, more laborious, and expensive CFU-based assays, helps distinguish bactericidal from bacteriostatic activity, and identifies compounds that are active under replicating conditions, nonreplicating conditions, or both. Results for 14 antimycobacterial compounds, including tuberculosis (TB) drugs, revealed that PA-824 (pretomanid) and TMC207 (bedaquiline) are largely bacteriostatic.